B Cells in Idiopathic Nephrotic Syndrome

Key facts

Sponsor

Mario Negri Institute for Pharmacological Research

Principal Investigator

Giuseppe Remuzzi, MD

Istituto Di Ricerche Farmacologiche Mario Negri

Intervention

Blood sampling(other)

Enrollment

21 target

Eligibility

6 years · All sexes

Timeline

2019 – 2024

Study locations (1)

• Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica, BG, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic nephrotic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06820866
  Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE3NCT05627557
  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
  Hoffmann-La Roche
• RECRUITINGNCT04207580
  A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
  University Hospital, Limoges

See all trials for Idiopathic nephrotic syndrome →